检查点抑制剂诱发的急性肝衰竭

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL

Journal of investigative medicine high impact case reports Pub Date : 2024-01-01 DOI:10.1177/23247096241261505

Chukwunonso Ezeani, Ogochukwu Ugochukwu, Adejoke Johnson, Daniel Lavie, Ryan Chauvin

{"title":"检查点抑制剂诱发的急性肝衰竭","authors":"Chukwunonso Ezeani, Ogochukwu Ugochukwu, Adejoke Johnson, Daniel Lavie, Ryan Chauvin","doi":"10.1177/23247096241261505","DOIUrl":null,"url":null,"abstract":"Immune checkpoint inhibitors have become essential antineoplastic agents in medical oncology over the past decade. However, they are associated with potentially fatal multisystem abnormalities, with increasing concern in gastrointestinal tract and its associated organs. We present a patient with advanced renal cell carcinoma, who presented with acute liver failure after the first dose of combined immunotherapy with nivolumab and ipilimumab. A thorough evaluation for viral, metabolic, and autoimmune causes was unremarkable. He was managed with steroids and made significant improvement. To our knowledge, this is the first documented case of acute liver failure following ipilimumab and nivolumab.","PeriodicalId":16198,"journal":{"name":"Journal of investigative medicine high impact case reports","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189009/pdf/","citationCount":"0","resultStr":"{\"title\":\"Checkpoint Inhibitor Induced Acute Liver Failure.\",\"authors\":\"Chukwunonso Ezeani, Ogochukwu Ugochukwu, Adejoke Johnson, Daniel Lavie, Ryan Chauvin\",\"doi\":\"10.1177/23247096241261505\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immune checkpoint inhibitors have become essential antineoplastic agents in medical oncology over the past decade. However, they are associated with potentially fatal multisystem abnormalities, with increasing concern in gastrointestinal tract and its associated organs. We present a patient with advanced renal cell carcinoma, who presented with acute liver failure after the first dose of combined immunotherapy with nivolumab and ipilimumab. A thorough evaluation for viral, metabolic, and autoimmune causes was unremarkable. He was managed with steroids and made significant improvement. To our knowledge, this is the first documented case of acute liver failure following ipilimumab and nivolumab.\",\"PeriodicalId\":16198,\"journal\":{\"name\":\"Journal of investigative medicine high impact case reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189009/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of investigative medicine high impact case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/23247096241261505\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of investigative medicine high impact case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23247096241261505","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

在过去的十年中，免疫检查点抑制剂已成为肿瘤内科学中必不可少的抗肿瘤药物。然而，这些药物与可能致命的多系统异常有关，其中胃肠道及其相关器官的异常日益受到关注。我们为您介绍一位晚期肾细胞癌患者，她在首次接受尼妥珠单抗和伊匹单抗联合免疫疗法后出现急性肝功能衰竭。对病毒、代谢和自身免疫原因的全面评估结果并无异常。他接受了类固醇治疗，病情明显好转。据我们所知，这是有据可查的首例因使用伊匹单抗和尼维单抗而出现急性肝功能衰竭的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Checkpoint Inhibitor Induced Acute Liver Failure.

Immune checkpoint inhibitors have become essential antineoplastic agents in medical oncology over the past decade. However, they are associated with potentially fatal multisystem abnormalities, with increasing concern in gastrointestinal tract and its associated organs. We present a patient with advanced renal cell carcinoma, who presented with acute liver failure after the first dose of combined immunotherapy with nivolumab and ipilimumab. A thorough evaluation for viral, metabolic, and autoimmune causes was unremarkable. He was managed with steroids and made significant improvement. To our knowledge, this is the first documented case of acute liver failure following ipilimumab and nivolumab.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of investigative medicine high impact case reports MEDICINE, GENERAL & INTERNAL-

CiteScore

1.90

自引率

0.00%

发文量

165

审稿时长

12 weeks

期刊介绍： The AFMR is committed to enhancing the training and career development of our members and to furthering its mission to facilitate the conduct of research to improve medical care. Case reports represent an important avenue for trainees (interns, residents, and fellows) and early-stage faculty to demonstrate productive, scholarly activity.